Powered by 
All the data and insights you need on Crinetics Pharmaceuticals Inc in one report.
$295
Buy Report View Sample
- Save hours of research time and resources with
our up-to-date Crinetics Pharmaceuticals Inc Strategy Report - Understand Crinetics Pharmaceuticals Inc position in the market,
performance and strategic initiatives. - Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
- Overview
- Financials
- Executives
- Locations
- Competitors
- Premium Data
- Lead Sheet
- Catalyst Calendar
- Clinical Trials
- Pipeline Drugs
- Regulatory Milestones
- Insights
Crinetics Pharmaceuticals Inc (Crinetics Pharmaceuticals) is a clinical stage pharmaceutical company. It develops novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related tumors. The company’s product pipeline includes paltusotine (Oral SST2 agonist) to treat acromegaly, CRN04777 (SST5 agonist) against congenital hyperinsulinism and CRN04894 (ACTH agonist) for treatment of cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals provides somatostatin for the treatment of pancreatic neuroendocrine tumors, carcinoid tumors, GH secreting adenomas, diabetic retinopathy, graves ophthalmopathy, chronic pain, epilepsy, and dementia. The company also develops other drug programs to treat polycystic kidney disorders, hyperparathyroidism and obesity. Crinetics Pharmaceuticals is headquartered in San Diego, California, the US.
Gain a 360-degree view of Crinetics Pharmaceuticals Inc and make more informed decisions for your business Gain a 360-degree view of Crinetics Pharmaceuticals Inc and make more informed decisions for your business Find out more
Headquarters United States of America
Address 10222 Barnes Canyon Rd Bldg 2, San Diego, California, 92121-2711
Website www.crinetics.com
Telephone 1 858 4506464
No of Employees 290
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange CRNX (NASD)
Revenue (2022) $4.0M -15.3% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ -30.9% (2022 vs 2021)
Market Cap* $3.3B
Net Profit Margin (2022) XYZ -54.5% (2022 vs 2021)
* As of and is in US$
View Crinetics Pharmaceuticals Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more
Crinetics Pharmaceuticals Inc premium industry data and analytics
80+
Lead Sheet
Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Crinetics Pharmaceuticals Inc’s relevant decision makers and contact details.
40+
Catalyst Calendar
Proactively evaluate Crinetics Pharmaceuticals Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
20+
Clinical Trials
Determine Crinetics Pharmaceuticals Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.
15+
Pipeline Drugs
Identify which of Crinetics Pharmaceuticals Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.
2
Regulatory Milestones
Track drug and patent expiries along with geographies impacted.
1
Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
1
IT Client Prospector provides intelligence on Crinetics Pharmaceuticals Inc’s likely spend across technology areas enabling you to understand the digital strategy.
Products and Services
| Products |
|---|
| Paltusotine (Oral SST2 Agonist): |
| Acromegaly |
| CRN04777 (SST5 Agonist): |
| XYZ |
| XYZ |
| XYZ |
Understand Crinetics Pharmaceuticals Inc portfolio and identify potential areas for collaboration Understand Crinetics Pharmaceuticals Inc portfolio and identify potential areas for collaboration Find out more
Competitor Comparison
| Key Parameters | Crinetics Pharmaceuticals Inc | ACEA Biosciences Inc | Actium Pharmaceuticals Inc | Albireo Pharma Inc | IVERIC bio Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | San Diego | San Diego | Houston | Boston | Parsippany |
| State/Province | California | California | Texas | Massachusetts | New Jersey |
| No. of Employees | 290 | - | - | - | 74 |
| Entity Type | Public | Private | Private | Private | Private |
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Key Financial Charts
Sales Growth
Net Income Growth
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Wendell Wierenga, Ph.D. | Chairman | Executive Board | 2015 | 75 |
| R. Scott Struthers, Ph.D. | Chief Executive Officer; Director; President | Executive Board | 2008 | 61 |
| Marc Wilson | Chief Financial Officer | Senior Management | 2018 | 44 |
| Jeff Knight | Chief Operating Officer | Senior Management | 2021 | 53 |
| Alan S. Krasner, M.D. | Chief Medical Officer | Senior Management | 2018 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Gain insight into Crinetics Pharmaceuticals Inc key executives to enhance your sales strategy Gain insight into Crinetics Pharmaceuticals Inc key executives to enhance your sales strategy Find out more
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
